

10696 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

116. Lindenbaum, J., J. J. Preibisz, V. P. Butler, Jr. and J. R. Saha, "Variation in Digoxin Bioavailability: A Continuing Problem," The Journal of Chronic Diseases, in press.
117. Thomas, R. and S. Aldous, "The Double Peak in the Plasma-Drug Curve After Oral Digoxin and Lanatoside C," The Lancet, p. 1267, Dec. 1, 1973.
118. Manninen, V. and A. Karhanen, "Inequal Digoxin Tablets," The Lancet, p. 1268, Dec. 1, 1973.
119. Jelliffe, R. W., "Factors to Consider in Planning Digoxin Therapy," Journal of Chronic Disease, 24:407, 1971.
120. Memorandum of telephone conversation dated December 6, 1973, regarding Digoxin Tablet Testing for Compliance with USP Monograph, Jerome P. Skelly, Ph.D. (Acting Supervisor, Division of Clinical Research, Office of Scientific Coordination, Bureau of Drugs, FDA) and Arthur W. Steers, Ph.D. (Director, National Center for Drug Analysis, FDA, St. Louis)
121. "Case Study No. 113: A Composite Case Study of Digoxin Tablets," FDA Case Studies of Drug Recalls May-June, 1971.
122. "Special Survey - Digoxin Tablets," Food and Drug Administration Compliance Program Guidance Manual Program, 7323.03, June 1, 1971.
123. "Drug Quality Control: Problem with Digoxin," Food and Drug Administration Drug Bulletin, p. 2, Oct. 1971.
124. "Results of Content Uniformity Data on Samples Received From John Lindenbaum," April 6, 1972.